BRAF and colorectal carcinoma: At the same time, in a study of CRC cells with the mutated BRAF phenotype and resistant to vemurafenib, it was revealed that the inhibition of BRAF by this compound produced a rapid activation of the EGFR growth factor receptor, which stimulated continuous proliferation in the presence of the BRAF inhibition [133].